Karen Daily Weinstein, DO
Hematology & Oncology · Gainesville, FLNPI 1770547648
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Merck accounts for 77.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $25,580 and has fallen 52.2% since, to $12,234 in 2025.
Across 49 payments — averaging $948.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$36K
- AstraZeneca$8K
- Gilead$652
- Eli Lilly$625
- Daiichi Sankyo Inc.$550
- Athenex Pharmaceutical Division, LLC$350
- plus $127 from 1 others
Across 22 payments — averaging $34,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$439K
- Merck$153K
- Astrazeneca UK Limited$143K
- F. Hoffmann-la Roche AG$19K
What the payments were for
- Consulting fees$9,20520%
- Speaking & faculty fees$24,78053%
- Grants$3501%
- Travel & lodging$11,37524%
- Food & beverage$7422%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 37 | $35,870 |
| AstraZeneca | 4 | $8,290 |
| Gilead | 3 | $652 |
| Eli Lilly | 1 | $625 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Hologic Sales And Service, LLC | 1 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,464 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 45 | $643,188 |
| IbrancePalbociclib | 23 | $354,147 |
| Letrozole | 570 | $13,333 |
| Exemestane | 61 | $10,157 |
| Tamoxifen Citrate | 53 | $2,226 |
| Anastrozole | 97 | $1,443 |
| Prochlorperazine Maleate | 47 | $1,292 |
| Ibandronate Sodium | 31 | $1,250 |
| Ondansetron Hcl | 49 | $1,067 |
| Olanzapine | 47 | $804 |
| Raloxifene Hcl | 17 | $518 |
| Dexamethasone | 27 | $498 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $246 |
| Duloxetine Hcl | 15 | $220 |
| Gabapentin | 12 | $212 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Gainesville
- George KimGainesville$361K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.